Dexrazoxane: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
Line 1: Line 1:
{{drugbox
{{DrugProjectFormSinglePage
| IUPAC_name = 4-[1-(3,5-dioxopiperazin-1-yl) propan-2-yl]piperazine-2,6-dione
|authorTag=
| image = Dexrazoxane.svg
 
| CAS_number = 24584-09-6
 
| ATC_prefix = V03
<!--Overview-->
| ATC_suffix = AF02
 
| ATC_supplemental =  
|genericName=
| PubChem = 71384
 
| DrugBank = APRD00090
 
| C = 11 | H = 16 | N = 4 | O = 4
 
| molecular_weight = 268.269 g/mol
|aOrAn=
| bioavailability =  
 
| protein_bound =  
a
| metabolism =  
 
| elimination_half-life =
|drugClass=
| excretion =  
 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
 
| pregnancy_US = <!-- A / B / C / D / X -->
 
| pregnancy_category =  
|indication=
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
 
| legal_UK = <!-- GSL / P / POM / CD -->
 
| legal_US = <!-- OTC / Rx-only -->
 
| legal_status =  
|hasBlackBoxWarning=
| routes_of_administration =  
 
}}
Yes
{{SI}}
 
{{CMG}}
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->


|drugBox=




'''Dexrazoxane hydrochloride''' (Zinecard [Pfizer for USA & Canada]; Cardioxane [Novartis for EU & ROW]) is a [[medication]] used to protect the [[heart]] against the [[cardiotoxic]] side effects of [[anthracycline]] [[chemotherapy]]. As a derivative of [[EDTA]], dexrazoxane [[chelate]]s [[iron]], but the precise mechanism by which it protects the heart is not known.


FDA has also approved a dexrazoxane hydrochloride drug, brand name Totect, for use as a treatment of [[extravasation]] resulting from IV [[anthracycline]] [[chemotherapy]].<ref>[http://www.fda.gov/cder/foi/label/2007/022025lbl.pdf Totect label on FDA's website]</ref> Extravasation is an [[adverse event]] in which chemotherapies containing anthracylines leak out of the blood vessel and [[necrotize]] the surrounding tissue.
<!--Mechanism of Action-->


==Clinical Pharmacology==
|mechAction=


===Mechanism of Action===
*


The mechanism by which Dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that Dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.
<!--Structure-->


===Pharmacokinetics===
|structure=


The pharmacokinetics of Dexrazoxane have been studied in advanced cancer patients with normal renal and hepatic function. Generally, the pharmacokinetics of Dexrazoxane can be adequately described by a two-compartment open model with first-order elimination. Dexrazoxane has been administered as a 15 minute infusion over a dose-range of 60 to 900 mg/m2 with 60 mg/m2 of doxorubicin, and at a fixed dose of 500 mg/m2 with 50 mg/m2 doxorubicin. The disposition kinetics of Dexrazoxane are dose-independent, as shown by linear relationship between the area under plasma concentration-time curves and administered doses ranging from 60 to 900 mg/m2. The mean peak plasma concentration of Dexrazoxane was 36.5 mcg/mL at the end of the 15 minute infusion of a 500 mg/m2 dose of Dexrazoxane administered 15 to 30 minutes prior to the 50 mg/m2 doxorubicin dose
*


Following a rapid distributive phase (~0.2 to 0.3 hours), Dexrazoxane reaches post-distributive equilibrium within two to four hours. The estimated steady-state volume of distribution of Dexrazoxane suggests its distribution primarily in the total body water (25 L/m2). The mean systemic clearance and steady-state volume of distribution of Dexrazoxane in two Asian female patients at 500 mg/m2 Dexrazoxane along with 50 mg/m2 doxorubicin were 15.15 L/h/m2 and 36.27 L/m2, respectively, but their elimination half-life and renal clearance of Dexrazoxane were similar to those of the ten Caucasian patients from the same study. Qualitative metabolism studies with Dexrazoxane have confirmed the presence of unchanged drug, a diacid-diamide cleavage product, and two monoacid-monoamide ring products in the urine of animals and man. The metabolite levels were not measured in the pharmacokinetic studies.
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


Urinary excretion plays an important role in the elimination of Dexrazoxane. Forty-two percent of the 500 mg/m2 dose of Dexrazoxane was excreted in the urine.
<!--Pharmacodynamics-->


Protein Binding: In vitro studies have shown that Dexrazoxane is not bound to plasma proteins.
|PD=


==Indications and Usage==
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


Dexrazoxane is indicated for reducing the incidence and severity of [[cardiomyopathy]] associated with [[doxorubicin]] administration in women with metastatic [[breast cancer]] who have received a cumulative [[doxorubicin]] dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. lt is not recommended for use with the initiation of [[doxorubicin]] therapy.
<!--Pharmacokinetics-->


==Contraindications==
|PK=


Dexrazoxane should not be used with chemotherapy regimens that do not contain an [[anthracycline]].
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.


==Overdosage==
<!--Nonclinical Toxicology-->


There have been no instances of drug overdose in the clinical studies sponsored by either Pharmacia & Upjohn Company or the National Cancer Institute. The maximum dose administered during the cardioprotective trials was 1000 mg/m2 every three weeks.
|nonClinToxic=


Disposition studies with Dexrazoxane have not been conducted in cancer patients undergoing dialysis, but retention of a significant dose fraction (>0.4) of the unchanged drug in the plasma pool, minimal tissue partitioning or binding, and availability of greater than 90% of the systemic drug levels in the unbound form suggest that it could be removed using conventional peritoneal or hemodialysis.
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.


There is no known antidote for Dexrazoxane. Instances of suspected overdose should be managed with good supportive care until resolution of myelosuppression and related conditions is complete. Management of overdose should include treatment of infections, fluid regulation, and maintenance of nutritional requirements.
<!--Clinical Studies-->


==Dosage and Administration==
|clinicalStudies=


The recommended dosage ratio of Dexrazoxane:doxorubicin is 10:1 (e.g., 500 mg/m2 Dexrazoxane:50 mg/m2 doxorubicin). In patients with moderate to severe renal dysfunction (creatinine clearance values <40 mL/min), the recommended dosage ratio of Dexrazoxane:doxorubicin is 5:1 (e.g., 250 mg/m2 Dexrazoxane:50 mg/m2 doxorubicin). Creatinine clearance can be determined from a 24 hour urinary creatinine collection or estimated using the Crockroft-Gault equation (assuming stable renal function):
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.


<!--How Supplied-->
    CLCR=[140-age (years)] x weight (kg) {x 0.85 for female patients}
    ———————————————————————————
    72 x serum creatinine (mg/dL)


Since a [[doxorubicin]] dose reduction is recommended in the presence of hyperbilirubinemia, the Dexrazoxane dosage should be proportionately reduced (maintaining the 10:1 ratio) in patients with hepatic impairment. Dexrazoxane must be reconstituted with 0.167 Molar (M/6) Sodium Lactate Injection USP to give a concentration of 10 mg Dexrazoxane for each mL of sodium lactate. The reconstituted solution should be given by slow I.V. push or rapid drip intravenous infusion from a bag. After completing the infusion of Dexrazoxane, and prior to a total elapsed time of 30 minutes (from the beginning of the Dexrazoxane infusion), the intravenous injection of doxorubicin should be given.
|howSupplied=


Reconstituted Dexrazoxane, when transferred to an empty infusion bag, is stable for 6 hours from the time of reconstitution when stored at 20° to 25°C (68° to 77°F), see USP controlled room temperature, or under refrigeration, 2° to 8°C (36° to 46°F). DISCARD UNUSED SOLUTIONS.
*


The reconstituted Dexrazoxane solution may be diluted with either 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a concentration range of 1.3 to 5 mg/mL in intravenous infusion bags. The resultant solutions are stable for 6 hours when stored at 20° to 25°C (68° to 77°F), see USP controlled room temperature, or under refrigeration, 2° to 8°C (36° to 46°F). DISCARD UNUSED SOLUTIONS.
<!--Patient Counseling Information-->


==Special Populations==
|fdaPatientInfo=


===Pediatric===
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


The pharmacokinetics of Dexrazoxane have not been evaluated in pediatric patients.
<!--Precautions with Alcohol-->


===Gender===
|alcohol=


Analysis of pooled data from two pharmacokinetic studies indicate that male patients have a lower mean clearance value than female patients (110 mL/min/m2 versus 133 mL/min/m2). This gender effect is not clinically relevant.
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


===Renal Insufficiency===
<!--Brand Names-->


The pharmacokinetics of Dexrazoxane were assessed following a single 15 minute IV infusion of 150 mg/m2 of Dexrazoxane in male and female subjects with varying degrees of renal dysfunction as determined by creatinine clearance (CLCR) based on a 24 hour urinary creatinine collection. Dexrazoxane clearance was reduced in subjects with renal dysfunction. Compared with controls, the mean AUC0-inf value was twofold greater in subjects with moderate (CLCR 30 to 50 mL/min) to severe (CLCR <30 mL/min) renal dysfunction. Modeling demonstrated that equivalent exposure (AUC0-inf) could be achieved if dosing were reduced by 50% in subjects with creatinine clearance values <40 mL/min compared with control subjects (CLCR >80 mL/min).
|brandNames=


===Hepatic Insufficiency===
* ®<ref>{{Cite web | title = | url = }}</ref>


The pharmacokinetics of Dexrazoxane have not been evaluated in patients with hepatic impairment. The Dexrazoxane dose is dependent upon the dose of doxorubicin. Since a doxorubicin dose reduction is recommended in the presence of hyperbilirubinemia, the dexrazone dosage is proportionately reduced in patients with hepatic impairment.
<!--Look-Alike Drug Names-->


===Drug Interactions===
|lookAlike=


There was no significant change in the pharmacokinetics of doxorubicin (50 mg/m2) and its predominant metabolite, doxorubicinol, in the presence of Dexrazoxane (500 mg/m2) in a crossover study in cancer patients.
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>


==Incompatibility==
<!--Drug Shortage Status-->


Dexrazoxane should not be mixed with other drugs.
|drugShortage=
}}


==References==
<!--Pill Image-->
<references/>


==Additional Resources==
{{PillImage
{{refbegin|2}}
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
* ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh,PA; Oncology Nursing Society; 1999:32-41.
|drugName=
* Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. NIH Publication No. 83-2621. For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402.
|NDC=
* AMA Council Report. Guidelines for Handling Parenteral Antineoplastics JAMA. 1985 March 15.
|drugAuthor=
* National Study Commission on Cytotoxic Exposure-Recommendations for Handling Cytotoxic Agents. Available from Louis P. Jeffrey, Sc.D., Chairman, National Study Commission on Cytotoxic Exposure, Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115.
|ingredients=
* Clinical Oncological Society of Australia. Guidelines and Recommendations for Safe Handling of Antineoplastic Agents. Med J Australia. 1983; 1:426-428.
|pillImprint=
* Jones RB. et al. Safe handling of Chemotherapeutic Agents: A report from the Mount Sinai Medical Center. CA - A Cancer Journal for Clinicians. 1983; (Sept/Oct) 258-263.
|dosageValue=
* American Society of Hospital Pharmacists Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm. 1990; 47:1033-1049.
|dosageUnit=
* Controlling Occupational Exposure to Hazardous Drugs. (OSHA WORK-PRACTICE GUIDELINES). Am J Health-Syst Pharm 1996; 53:1669-1685.
|pillColor=
{{refend}}
|pillShape=
|pillSize=
|pillScore=
}}


{{Detoxifying agents for antineoplastic treatment}}
<!--Label Display Image-->


[[Category:Chelating agents]]
{{LabelImage
[[Category:Chemotherapeutic adjuvants]]
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
[[Category:Imides]]
}}
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


<!--Category-->


{{WH}}
[[Category:Drug]]
{{WS}}

Revision as of 20:43, 4 February 2015

Dexrazoxane
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Dexrazoxane is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Dexrazoxane in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dexrazoxane in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Dexrazoxane in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Dexrazoxane in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Dexrazoxane in pediatric patients.

Contraindications

  • Condition1

Warnings

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Dexrazoxane in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Dexrazoxane in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dexrazoxane in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Dexrazoxane during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Dexrazoxane with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Dexrazoxane with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Dexrazoxane with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Dexrazoxane with respect to specific gender populations.

Race

There is no FDA guidance on the use of Dexrazoxane with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Dexrazoxane in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Dexrazoxane in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Dexrazoxane in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Dexrazoxane in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Dexrazoxane in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Dexrazoxane in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Dexrazoxane in the drug label.

Pharmacology

There is limited information regarding Dexrazoxane Pharmacology in the drug label.

Mechanism of Action

Structure

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Dexrazoxane in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Dexrazoxane in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Dexrazoxane in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Dexrazoxane in the drug label.

How Supplied

Storage

There is limited information regarding Dexrazoxane Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Dexrazoxane |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Dexrazoxane |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Dexrazoxane in the drug label.

Precautions with Alcohol

  • Alcohol-Dexrazoxane interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Dexrazoxane
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Dexrazoxane
 |Label Name=Dexrazoxane11.png

}}


{{#subobject: 

 |Label Page=Dexrazoxane
 |Label Name=Dexrazoxane11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Dexrazoxane&oldid=1063593"